Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Cheryl McDonald"'
Autor:
Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong
Publikováno v:
HIV Research & Clinical Practice, Vol 20, Iss 1, Pp 24-33 (2019)
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-week efficacy and safety of D/C/F/TAF versus darunavir/c
Externí odkaz:
https://doaj.org/article/2398a84fc10a4d59a8c3ed8590f56b34
Autor:
Samir K, Gupta, Mezgebe, Berhe, Gordon, Crofoot, Paul, Benson, Moti, Ramgopal, James, Sims, Cheryl, McDonald, Peter, Ruane, William E, Sanchez, Anita, Scribner, Shan-Yu, Liu, Laurie A, VanderVeen, Hadas, Dvory-Sobol, Martin S, Rhee, Jared M, Baeten, Ellen, Koenig
Publikováno v:
The Lancet HIV. 10:e15-e23
Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes use of a unique mechanism, can be administered orally or subcutaneously. We so
Autor:
Juan Pulido, Michael Boger, John Hollingsworth, Homero Paniagua, Lucas GuimarÃes, Lisa Davidson, Victor Matheus Rolim de Souzafrom, Ana Elizabeth G. Maldonado, Colleen F. Kelley, Ricardo Diaz, Caitlin Moran, Jennifer Fulton, Ana Carolina M. Beheregaray, Valeria Telles, Khang Vo, Cameron Durrant, Omar Ahmed, Alpesh Amin, Daniel Barbaro, EstevÃo Figueiredo, David Weinrib, Noah Wald-Dickler, Daniel Wagner de Castro Lima Santos, Rebeca C. Lacerda Garcia, Brian Metzger, Paulo Ferreira, Andrew Miller, Marina Andrade Lima, Wilfred Onyia, William S Aronstein, Chrisoula Politis, Maqsood Alam, Celso Silva, Ana Maria T. Ortiz, Julia Minghini, Gualter CanÇado, Charles D. Burger, Mindy Sampson, Martin Cearras, Anne Frosch, Maysa B. Alves, Roy Poblete, Felipe Dal Pizzol, Carmen Polito, TÁcito do Nascimento JÁcome, Adilson Joaquim Westheimer Cavalcante, John Burk, Camila Anton, Eveline Pipolo Milan, Cristiane Ritter, Vincent C. Marconi, Dale Chappell, Loni Dorigo, Ricardo Albaneze, Renata Bezerra Onofre, Carlos del Rio, Miki Watanabe, Joshua Berg, Claudia R. Libertin, Janine Soares de Castro, Seife Yohannes, Juvencio José Duailibe Furtado, Linda Sher, May M. Lee, Robert Orenstein, Obinna Okoye, Linh Ngo, Jeffrey Lennox, Richard Zuckerman, Stephanie Strollo, Lakshmi Sambathkumar, Jason Sniffen, Paula Pietrobom, Kiran Gajurel, Lewis McCurdy, Matheus José Barbosa Moreira, Subarna Biswas, Valeria Cantos, Ana Caroline Iglessias, Jason Baker, Leopoldo T. Trevelin, John Gharbin, Victor Barreto Garcia, Marcelo B. Vinhas, Kleber Luz, Henrikki Antila, Fernando Carvalho Neuenschwander, Zelalem Temesgen, Cheryl McDonald, Sara Zulfigar, Michael Leonard, Fabiano Ramos, Gabrielle Chappell, William Gill, Martti Anton Antila, Anandi Sheth, Meghan Lewis, Sheetal Kandiah, Michael Bowdish, Lanny Hsieh, Paulina Rebolledo, Francini Correa, Chaitanya Mandapakala, Stuart McDonald, Natalia Bacellar, Zainab Shahid, Victoria M Catterson, Matthew Robinson, Rebeca Brugnolli, Richard Lee, Marina de A. R. Da Silva, Amay Parikh, Anup Patel, Gustavo Araujo, Andrew D. Badley, Caroline Uber Ghisi, Roberto Patron, Douglass Hutcheon, Marianna M. Lago, Christopher Polk, Nestor Quezada, Lionel Lewis, Marina Salgado Miranda, Lydia Lam
Publikováno v:
The Lancet. Respiratory Medicine
Summary Background The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute
Autor:
Olayemi Osiyemi, Indira Brar, Moti Ramgopal, Diana M. Brainard, Anson K Wurapa, Princy Kumar, Daniel S Berger, Hal Martin, Kristen Andreatta, Braave Investigators, Michael S. Saag, Sean E Collins, Debbie Hagins, Corrilynn O. Hileman, Christiana Blair, Cheryl McDonald
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Supplemental Digital Content is Available in the Text.
Background: With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research. Setting: BRAAVE (NCT03631732) is a randomized, phase
Background: With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research. Setting: BRAAVE (NCT03631732) is a randomized, phase
Autor:
Cheryl McDonald, Cristina Mussini, Donghan Luo, Eric Y Wong, Christoph D. Spinner, Kimberley Brown, John Jezorwski, Erika Van Landuyt, Bruce Rashbaum
Publikováno v:
HIV Research & Clinical Practice. 20:24-33
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-wee...
Autor:
Jon Spindler, Jenny McFarlane, Cheryl McDonald, Karen Kuncze, Kathryn Jee, Matthew A Spinelli, Patricia Defechereux, Monica Gandhi, Brentton Lowery, Robert M. Grant, Mary F. Kearney, Dawn K. Smith, Jennifer A Shuford, Peter L. Anderson, Nhi Phung, Hideaki Okochi, DeeJay Johannessen
Publikováno v:
Clin Infect Dis
Cases of seroconversion on pre-exposure prophylaxis (PrEP) should be carefully investigated, given their public health implications and rarity. We report a case of transmitted drug resistance causing seroconversion on PrEP in spite of high adherence,
Publikováno v:
Journal of Interprofessional Care. 31:546-549
The number of older adults with multiple complex comorbidities and frailty is expected to increase dramatically in the coming decades, which will necessitate a concomitant increase in the need for skilled clinicians who are able to manage complex ger
Autor:
Hal Martin, Sean E Collins, Christiana Blair, Princy Kumar, Anson K Wurapa, Daniel S Berger, Cheryl McDonald, Kristen Andreatta, Debbie Hagins, Moti Ramgopal, Olayemi Osiyemi, Diana M. Brainard, Michael S. Saag, Indira Brar, Corrilynn O. Hileman
Publikováno v:
Open Forum Infectious Diseases
Background Black Americans are disproportionately impacted by HIV. The BRAAVE 2020 study, evaluated the safety and efficacy of switching to the guidelines-recommended single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) i
Autor:
Douglas Cunningham, D. Ward, Mamta K. Jain, Faiza Ajana, Magda Opsomer, Anita Rachlis, Sharon Walmsley, Frank A. Post, Anders Blaxhult, Amanda Clarke, M. J. Galindo, Marcel Stoeckle, P.-M. Girardy, Karam Mounzer, David Shamblaw, U. F. Bredeek, L. Bhatti, J. J. Eron, Andrew Ustianowski, Mar Gutierrez, John Jezorwski, Javier O Morales-Ramirez, Antonio Rivero, M.A. Johnson, Gatell Jm, Erika Van Landuyt, Stéphane De Wit, A. Wilkin, Laurent Cotte, Cheryl McDonald, D. Murphy, Cynthia Brinson, Romana Petrovic, Olayemi Osiyemi, J. de Vente, I. Poizot-Martin, Juan Berenguer, Robin Dretler, J. Bailey, B. Rashbaum, Moti Ramgopal, A. Scribner, Yazdan Yazdanpanah, Eric Florence, A. Piekarska, Brian Gazzard, Chloe Orkin, W. Halota, Gary Richmond, Jacques Reynes, C. Ricart, C. Lucasti, Ignacio Pérez-Valero, Jason Brunetta, S. Shafran, Daniel Podzamczer, Franco Antonio Felizarta, Claudia Martorell, F. Post, Peter Ruane, Edwin DeJesus, J. Portilla Sogorb, C. Orkin, K. Tashima, Federico Pulido, Bernard Vandercam, F. Pulido, José L. Casado, Christine Katlama, Kimberley Brown, J Gasiorowski, A. Witor, Joseph J. Eron, Brian Conway, Andri Rauch, Jose R. Arribas, Michel Moutschen, H. Olivet, A. Scarsella, Leo Flamholc, A. Horban, D. Cunningham, Ronald Nahass, Félix Gutiérrez, G. Huhn, W.K. Henry, A. Thalme, S De Wit, Jan Fehr, Debbie Hagins, José Antonio Iribarren, J.-M. Molina, S. Henn, F Raffi, Juan A. Pineda, Marina B. Klein, Eugenia Negredo, Hernando Knobel, J. Slim, P. Benson, L. Waters, E. Teicher, Linos Vandekerckhove, Craig A. Dietz, Magnus Gisslén, Joel E. Gallant, J. Gathe, P. Shalit, D. Prelutsky, G. Voskuhl, D. Rey, E. Van Wijngaerden, Anthony Mills, Erkki Lathouwers, Carl J. Fichtenbaum, I. Brar, Gordon Crofoot, Veerle Hufkens, I. Santos Gil
Publikováno v:
Antiviral Research
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017eb51bc97390ae19e12fb2aea5fdc8
http://hdl.handle.net/2445/171213
http://hdl.handle.net/2445/171213
Autor:
Peter Ackerman, Stephanie Noviello, Cheryl McDonald, Rafia Bhore, Anne F Luetkemeyer, Moti Ramgopal
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In human immunodeficiency virus (HIV)-hepatitis C virus-coinfected patients, 12 weeks' daclatasvir + sofosbuvir once-daily provided ≥95% sustained virologic response 12 weeks post-treatment across a broad range of antiretroviral regimens, was well